TruScreen Appoints Uzbekistan Distributor

NZX/ASX Announcement

28 May 2026


TruScreen appoints Uzbekistan distributor and commences pilot clinical study

• Albatros Health Care LLC appointed as Uzbekistan distributor
• Sales revenue potential is USD740,000 (NZD1.26m) to the end of 2028
• Approval for commencement of c600 patient pilot clinical study in Tashkent, Uzbekistan
expected by early June 2026
• Study results to provide validation data to support TruScreen use nationally, in public and
private healthcare settings

TruScreen Group Limited (NZX/ASX: TRU) (TruScreen or the Company), a global leader in AI-enabled
cervical cancer screening, is pleased to announce the appointment of Albatros Health Care LLC as its
distributor in Uzbekistan and the commencement of a pilot clinical study in Tashkent to support market
entry.

Uzbekistan distributor appointed

TruScreen appointed Albatros Health Care LLC on 18 May 2026.

Albatros is an Uzbek medical device distributor established in 2017 that provides modern medical
technologies into Uzbekistan. It has a nationwide sales network and works closely with government
stakeholders.

Sales revenue potential is USD740,000 (NZD1.26m) over the 30-month period to the end of 2028. The
first batch of TruScreen screening devices was shipped this week to Uzbekistan to support launch
activities, training and the pilot clinical study in Tashkent.

Pilot clinical study in Tashkent

A pilot clinical study will commence following ethics approval received in May 2026. The study will be
conducted at Obstet Gynecol Clinic in Tashkent and will enrol approximately 600 participants over a
month.

As per the Memorandum of Understanding signed in August 2025, the objectives of the program are:
1. To assess cervical screening options for the women of Uzbekistan and the implementation of
TruScreen in the most effective way to prevent cervical cancer deaths, and to determine the
accuracy, reliability and operational requirements of TruScreen compared to Pap smear in
detecting early cancerous changes in the cervix.
2. To develop a National Cervical Cancer Screening program for Uzbekistan

The clinical study results are expected to provide validation data for TruScreen to support use in both
public and private healthcare settings in Uzbekistan. The country has 11.32 million women of
screening age*, and cervical cancer ranks as the second most frequent cancer among women,
providing significant growth opportunity for reduction in cervical cancer deaths.
The study will be led by Dr Pakhomova as principal investigator, with Dr Klara Yadgorava acting as
advisor overseeing the project. Dr Yadgarova is a World Health Organization national consultant for
Uzbekistan and a consultant for Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ)
GmbH (a German based global NGO) on Uzbekistan projects.

Training and launch support

Senior TruScreen clinical managers will support the pilot project and the launch of TruScreen in
Uzbekistan, in July 2026. The training program is intended to support both clinical users of the TruScreen
device and the Albatros sales team ahead of broader commercial rollout.

Strategic significance

Uzbekistan is a significant market and a regional healthcare centre for neighbouring Central Asian
“Stans” nations where TruScreen’s innovative, real-time technology would be equally well-suited for
public screening adoption.

TruScreen’s market expansion is accelerating through increasing recognition from healthcare
professionals, governments and NGOs as a solution to the challenges of conducting public cervical
cancer screening programs in emerging markets. TruScreen is in advanced discussions with potential
distributors in several additional countries, consistent with its strategy of expanding through capable
local partners in key emerging markets.

Executive Chairman Tony Ho said:

“We are pleased to appoint Albatros Health Care as TruScreen’s distributor in Uzbekistan and to
commence this important pilot clinical study in Tashkent. Uzbekistan represents a compelling market
opportunity, and we believe TruScreen’s real-time, AI-enabled cervical cancer screening technology is
well suited to local screening needs, particularly where scalable public screening solutions are required.

The pilot study will generate valuable local data to support broader adoption in both the public and
private sectors. Together with Albatros’ nationwide network and government relationships, this initiative
provides a strong platform for TruScreen’s growth in Uzbekistan and the wider Central Asian region.”

This announcement has been approved by the Board.


* Female population ages 15-64, Source: World Population Prospects, United Nations Population Division, World Bank

For more information, visit
www.truscreen.com
or contact:

TruScreen Group Limited
Tony Ho
Executive Chairman
info@truscreen.com


About TruScreen
TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand and Australian listed company with a real-
time, AI-enabled cervical cancer screening technology designed to detect pre-cancerous and
cancerous changes of the cervix.
The TruScreen device is registered for use in multiple markets and has been used to screen more than
1,000,000 women worldwide.


TruScreen’s technology is designed to support cervical cancer screening in settings where access to
laboratory infrastructure and specialist pathology services may be limited, making it well suited to
emerging markets and public screening initiatives.